From GlobeNewswire: 2025-05-31 08:00:00

Xilio Therapeutics announced preliminary results from a Phase 2 clinical trial showing a 26% objective response rate in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC). Responses were deep and durable, with improvements in clinical symptoms and reductions in tumor biomarkers. The combination therapy also demonstrated a differentiated safety profile with low incidence of adverse events. These findings are being presented at the 2025 ASCO Annual Meeting. The trial evaluated vilastobart in combination with atezolizumab in patients with MSS CRC and without liver metastases, with responses ongoing for up to 37 weeks.



Read more at GlobeNewswire: Xilio Therapeutics Announces Updated Phase 2 Data for